Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Emily M Dolce"'
Autor:
Andi K. Cani, Emily M. Dolce, Elizabeth P. Darga, Kevin Hu, Chia‐Jen Liu, Jackie Pierce, Kieran Bradbury, Elaine Kilgour, Kimberly Aung, Gaia Schiavon, Danielle Carroll, T. Hedley Carr, Teresa Klinowska, Justin Lindemann, Gayle Marshall, Vicky Rowlands, Elizabeth A. Harrington, J. Carl Barrett, Nitharsan Sathiyayogan, Christopher Morrow, Valeria Sero, Anne C. Armstrong, Richard Baird, Erika Hamilton, Seock‐Ah Im, Komal Jhaveri, Manish R. Patel, Caroline Dive, Scott A. Tomlins, Aaron M. Udager, Daniel F. Hayes, Costanza Paoletti
Publikováno v:
Molecular Oncology, Vol 16, Iss 10, Pp 1969-1985 (2022)
Nearly all estrogen receptor (ER)‐positive (POS) metastatic breast cancers become refractory to endocrine (ET) and other therapies, leading to lethal disease presumably due to evolving genomic alterations. Timely monitoring of the molecular events
Externí odkaz:
https://doaj.org/article/3982ed92674c47fd83894acff6f5a9d3
Autor:
Costanza Paoletti, Meredith M. Regan, Samuel M. Niman, Emily M. Dolce, Elizabeth P. Darga, Minetta C. Liu, P. Kelly Marcom, Lowell L. Hart, John W. Smith, Karen L. Tedesco, Eitan Amir, Ian E. Krop, Angela M. DeMichele, Pamela J. Goodwin, Margaret Block, Kimberly Aung, Martha E. Brown, Robert T. McCormack, Daniel F. Hayes
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-9 (2021)
Abstract Circulating tumor cells (CTC) are prognostic in metastatic breast cancer (MBC). The CTC-endocrine therapy index (CTC-ETI), consisting of CTC-ER (estrogen receptor), BCL2, human epidermal growth factor receptor (HER2), and Ki67 expression, mi
Externí odkaz:
https://doaj.org/article/a4591a6d3a9d4069a97a9133183bb04c
Autor:
Elizabeth P. Darga, Emily M. Dolce, Fang Fang, Kelley M. Kidwell, Christina L. Gersch, Steven Kregel, Dafydd G. Thomas, Anoop Gill, Martha E. Brown, Steven Gross, Mark Connelly, Michael Holinstat, Erin F. Cobain, James M. Rae, Daniel F. Hayes, Costanza Paoletti
Publikováno v:
PLoS ONE, Vol 16, Iss 11 (2021)
Background Immune checkpoint inhibition is effective in several cancers. Expression of programmed death-ligand 1 (PD-L1) on circulating tumor or immune effector cells could provide insights into selection of patients for immune checkpoint inhibition.
Externí odkaz:
https://doaj.org/article/63089b9215d1428799266b1d9644f894
Autor:
Daniel F. Hayes, William E. Barlow, Jeffrey B. Smerage, Gabriel N. Hortobagyi, Julie R. Gralow, Gerald V. Doyle, Madeline I. Repollet, Elizabeth P. Darga, Emily M. Dolce, Jieling Miao, Costanza Paoletti
Purpose:Metastasis requires malignant cell circulation from the primary to a distant tissue. Elevated levels of circulating tumor cells (CTC) portend a poor prognosis in breast and other cancers. Recent studies have suggested that CTC clusters may be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::142dbe13adaa6ee72311933b1b81e687
https://doi.org/10.1158/1078-0432.c.6527888.v1
https://doi.org/10.1158/1078-0432.c.6527888.v1
Autor:
Daniel F. Hayes, Richard Baird, J. Carl Barrett, Elizabeth A. Harrington, Caroline Dive, Fouziah Butt, Nadia Iqbal, Seock-Ah Im, Komal Jhaveri, Anne Armstrong, Manish Patel, Erika Hamilton, Kimberly Aung, Nitharsan Sathiyayogan, Vicky Rowlands, Parul Patel, Shethah Morgan, Gayle Marshall, Justin Lindemann, Teresa Klinowska, Matthias Hoch, Joseph Geradts, T. Hedley Carr, Elizabeth P. Darga, Emily M. Dolce, Gaia Schiavon, Costanza Paoletti
Supplementary Figures: Supplementary Figure 1. Summary of duration on AZD9496 therapy, previous therapies, and circulating biomarkers status at baseline for each patient ranked by ascending dose; Supplementary Figure 2. Tumor pharmacodynamics. Supple
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a52dc9d60aefb975153d05abcb1fe32
https://doi.org/10.1158/1078-0432.22469739.v1
https://doi.org/10.1158/1078-0432.22469739.v1
Autor:
Daniel F. Hayes, Richard Baird, J. Carl Barrett, Elizabeth A. Harrington, Caroline Dive, Fouziah Butt, Nadia Iqbal, Seock-Ah Im, Komal Jhaveri, Anne Armstrong, Manish Patel, Erika Hamilton, Kimberly Aung, Nitharsan Sathiyayogan, Vicky Rowlands, Parul Patel, Shethah Morgan, Gayle Marshall, Justin Lindemann, Teresa Klinowska, Matthias Hoch, Joseph Geradts, T. Hedley Carr, Elizabeth P. Darga, Emily M. Dolce, Gaia Schiavon, Costanza Paoletti
Purpose:Common resistance mechanisms to endocrine therapy (ET) in estrogen receptor (ER)–positive metastatic breast cancers include, among others, ER loss and acquired activating mutations in the ligand-binding domain of the ER gene (ESR1LBDm). ESR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32d19b6ff53bf7d9bdb2da2810051c15
https://doi.org/10.1158/1078-0432.c.6527325.v1
https://doi.org/10.1158/1078-0432.c.6527325.v1
Autor:
Afroditi Nanou, Jieling Miao, Frank A.W. Coumans, Emily M. Dolce, Elizabeth Darga, William Barlow, Jeffrey B. Smerage, Costanza Paoletti, Andrew K. Godwin, Lajos Pusztai, Priyanka Sharma, Alastair Thompson, Gabriel N. Hortobagyi, Leon W.M.M. Terstappen, Daniel F. Hayes
Publikováno v:
JCO Precision Oncology, 7:e2200372. American Society of Clinical Oncology
PURPOSE Circulating tumor cells (CTCs) are strongly prognostic for overall survival (OS) in metastatic breast cancer although additional prognostic biomarkers are needed. We evaluated the complementary prognostic value of tumor‐derived extracellula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::160b29b89bd03a42f51e0957d621a4c5
https://doi.org/10.1200/po.22.00372
https://doi.org/10.1200/po.22.00372
Autor:
Seock-Ah Im, Jackie Pierce, Kevin Hu, Gayle Marshall, Chia Jen Liu, Manish R. Patel, Scott A. Tomlins, TH Carr, Danielle Carroll, Komal Jhaveri, Daniel F. Hayes, Costanza Paoletti, Richard D. Baird, Justin P.O. Lindemann, Andi K. Cani, Anne C Armstrong, Gaia Schiavon, Aaron M. Udager, J.C. Barrett, Emily M. Dolce, Elizabeth P. Darga, Erika Hamilton, Kimberly Aung, Martha E. Brown, Kieran Bradbury, Teresa Klinowska, Vicky Rowlands, Caroline Dive, Elizabeth A. Harrington
Purpose: The vast majority of advanced ER POS breast cancers eventually cease responding to endocrine (ET) and other therapies leading to evolution of lethal disease. However, timely monitoring of the molecular events associated with response/progres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7ce778bda093ecc2d1fb9ffe222d2c2
https://www.repository.cam.ac.uk/handle/1810/349666
https://www.repository.cam.ac.uk/handle/1810/349666
Autor:
Andi K. Cani, Emily M. Dolce, Elizabeth P. Darga, Kevin Hu, Chia-Jen Liu, James M. Rae, Daffyd G. Thomas, Scott A. Tomlins, Arul M. Chinnaiyan, Aaron M. Udager, Costanza Paoletti, Erin F. Cobain, Daniel F. Hayes
Publikováno v:
Cancer Research. 82:1700-1700
Clinical decisions for precision and immuno-oncology therapies are based on predictive biomarkers commonly obtained from a single metastatic biopsy, or from archived primary tumor material. Circulating genomic biomarkers present a minimally invasive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73a7cf618f94cfd1b72ed68b9d4c06a5
https://doi.org/10.1158/1538-7445.am2022-1700
https://doi.org/10.1158/1538-7445.am2022-1700
Autor:
Andi K. Cani, Emily M. Dolce, Chia-Jen Liu, Brittany Rupp, Elizabeth P. Darga, Costanza Paoletti, Dafydd G. Thomas, Yi-Mi Wu, Dan R. Robinson, Sunitha Nagrath, Arul M. Chinnaiyan, Scott A. Tomlins, Aaron M. Udager, John M. Carethers, Erin F. Cobain, Daniel F. Hayes
Publikováno v:
Cancer Research. 82:611-611
The success of immune checkpoint inhibitors rests on biomarkers such as tumor mutation burden (TMB) and microsatellite instability (MSI), both FDA-approved predictors of anti PD-1/L1 therapy benefit. Tissue biopsies often collected once in the metast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a14c00b79181d6637f68fca557995919
https://doi.org/10.1158/1538-7445.am2022-611
https://doi.org/10.1158/1538-7445.am2022-611